•
Sep 30, 2021
Johnson & Johnson Q3 2021 Earnings Report
Reported solid performance driven by Pharmaceuticals, Medical Devices recovery, and Consumer Health growth.
Key Takeaways
Johnson & Johnson reported a total sales growth of 10.7% to $23.3 Billion with operational growth of 9.9%. Earnings per share increased by 3.0% to $1.37, and adjusted earnings per share increased by 18.2% to $2.60. The company is increasing its 2021 full-year guidance.
Total sales growth of 10.7% to $23.3 Billion.
Operational growth of 9.9% and adjusted operational growth of 10.6%.
Earnings per share of $1.37, a 3.0% increase.
Adjusted earnings per share of $2.60, an 18.2% increase.
Johnson & Johnson
Johnson & Johnson
Forward Guidance
Johnson & Johnson is increasing its 2021 full-year guidance.